Background: Doxorubicin (DOX) can induce significant cardiotoxicity and compromise the safety of its clinical application. This study explored the cardioprotective potential of tirzepatide against DOX-induced cardiotoxicity. Methods: In this study, we employed both in vitro and in vivo DOX injury models to systematically assess cardiac function and myocardial tissue structure through echocardiography and histopathological analysis. Additionally, we examined mitochondrial ultrastructure using transmission electron microscopy (TEM) and evaluated mitochondrial membrane potential (MMP). Results: Our findings revealed that tirzepatide administration significantly enhanced cardiac systolic performance and reduced myocardial damage. Notably, tirzepatide effectively preserved mitochondrial function by maintaining cristae integrity and restoring MMP. Conclusions: These results demonstrate that tirzepatide confers protection against DOX-induced cardiotoxicity primarily through the amelioration of mitochondrial dysfunction.